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trials. One such measure is the FACT-Leukemia questionnaire (FACT-Leu), which 
evaluates the quality of life (QOL) of leukemia patients. METHODS: This study set 
out to linguistically validate the FACT-Leu for use in Argentina, Austria, Belgium, 
Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, Egypt, Finland, 
France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Latvia, Lithua-
nia, Malaysia, Mexico, The Netherlands, Norway, Poland, Romania, Russia, Serbia, 
Slovak Republic, Slovenia, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, 
Ukraine and Venezuela. The study sample consisted of 758 patients (444 males/310 
females/4 missing) diagnosed with leukemia. Patient mean age was 47 years, and at 
the time of administration, 628 patients were receiving medical treatment. The sample 
consisted of patients who speak 43 languages collectively. The FACT-Leu was trans-
lated according to the standard FACIT methodology. Patients diagnosed with Leuke-
mia completed the respective translated questionnaire and then participated in a 
cognitive interview to determine if there were any problems with the translations or 
item content. Quantitative analyses (descriptive statistics and reliability analyses) were 
performed on the combined sample and participant comments were analyzed qualita-
tively in order to conﬁrm the validity of the translations. RESULTS: The FACT-Leu 
translations exhibited good internal reliability and linguistic validity. The alpha coef-
ﬁcient for the questionnaire as a whole including all languages was 0.96. Subscale 
alphas ranged from 0.81 to 0.91, also indicating good internal consistency. All items 
on the FACT-Leu correlated at an acceptable level. CONCLUSIONS: The FACT-Leu 
demonstrated acceptable reliability and linguistic validity in all 43 languages. We 
consider these translations acceptable for PRO assessment in international research 
and clinical trials.
PCN136
COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AMONG 
LOCAL STAGE PROSTATE CANCER PATIENTS: TYPES, FACTORS 
ASSOCIATED WITH USE AND PERCEIVED BENEFITS
Ramsey SD1, McDermott CL1, Zeliadt SB2, Blough DK3, Fedorenko CR1, Arora NK4, 
Penson DF5, Oakley-Girvan I6, Hamilton AS7, Van Den Eeden SK8, Potosky AL9
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2VA Puget Sound Health 
Care System, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA, 4National 
Cancer Institute, Bethesda, MD, USA, 5University of Southern California / Norris Cancer 
Center, Los Angeles, CA, USA, 6Northern California Cancer Center, Fremont, CA, USA, 
7USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA, 8Kaiser Permanente, 
Oakland, CA, USA, 9Georgetown University Medical Center, Washington, DC, USA
OBJECTIVES: Little is known about CAM use among prostate cancer patients. This 
study describes CAM use, patient factors that predicted CAM use, and satisfaction 
with CAM among men with local stage prostate cancer. METHODS: Newly diag-
nosed local stage prostate cancer patients in California and Washington State com-
pleted self-administered surveys. Patients were asked about sources of information 
they used to learn about prostate cancer, and at six months, about types of CAM they 
were using and satisfaction with those therapies. RESULTS: A total of 512 men 
completed baseline surveys before treatment and six-month follow-up surveys. 261 
(51%) reported using CAM at follow-up. The average age was 65; 69% were white, 
11% black, 10% Asian; 128 (49%) had “low risk” local stage prostate cancer by PSA 
and Gleason score. The most common forms of CAM utilized included personal prayer 
(n  148, 57%), herbs or dietary supplements (n  86, 33%), and special diets (n  
84, 32%). Fifty-one percent used one type of CAM, 26% used two, and 22% used 
three or more. In multivariate analysis, patients were signiﬁcantly more likely to use 
CAM if they had consulted medical literature (OR 1.96, CI 1.23–3.11) or talked with 
friends or family members (OR 1.76, CI 1.17–2.64). Prostate cancer risk group, 
comorbidities, age, race, education level, marital status, employment, and income were 
not signiﬁcantly associated with CAM use. Most described CAM as “very” or “some-
what” helpful” (92%). Many CAM users [43% (n  113)] did not discuss CAM with 
a health professional. CONCLUSIONS: In this multi-site study, more than half of all 
men with local stage prostate cancer reported using CAM. Race and education were 
not predictors of use. A substantial minority of CAM users did not discuss these 
treatments with their physician. Since no CAM approach has demonstrated beneﬁt 
for local stage prostate cancer, future research should examine men’s perceptions of 
the beneﬁts.
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OBJECTIVES: To review PRO labelling claims achieved in oncology in Europe and 
in the US and consider the beneﬁts, and challenges faced. METHODS: PROLabels 
database was searched to identify oncology products with PRO labeling approved in 
Europe since 1995 or in the US since 1998. FDA and EMEA websites and guidance 
documents were reviewed. PUBMED was searched for articles on PRO claims in 
oncology. RESULTS: Among all oncology products approved, 19 were identiﬁed with 
PRO claims; nine in the U.S, ﬁve in Europe, and ﬁve in both. The language used in 
the labelling was limited to beneﬁt (e.g. “. . . resulted in symptom beneﬁts by signiﬁ-
cantly prolonging time to deterioration in cough, dyspnoea, and pain, versus placebo”) 
and equivalence (e.g. “no statistical differences were observed between treatment 
groups for global QOL”). Seven products used a validated HRQL tool; two used 
symptom tools; two used both; seven used single-item symptom measures (one was 
unknown). The following emerged as likely reasons for success: ensuring systematic 
PRO data collection; clear rationale for pre-speciﬁed endpoints; adequately powered 
trials to detect differences and clinically signiﬁcant changes; adjusting for multiplicity; 
developing an a priori statistical analysis plan including primary and subgroup analy-
ses, dealing with missing data, pooling multiple-site data; establishing clinical versus 
statistical signiﬁcance; interpreting failure to detect change. End-stage patient drop-out 
rates and cessation of trials due to exceptional therapeutic beneﬁt pose signiﬁcant 
challenges to demonstrating treatment PRO improvement. CONCLUSIONS: PRO 
labelling claims demonstrate treatment impact and the trade-off between efﬁcacy and 
side effects ultimately facilitating product differentiation. Reliable and valid instru-
ments speciﬁc to the desired language, claim, and target population are required. 
Practical considerations include rationale for study endpoints, transparency in assump-
tions, and attention to subtle variations in data.
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OBJECTIVES: The identiﬁcation and management of unmet supportive care needs is 
an essential component of health care for people with cancer. The study aimed to 
evaluate the informative, psychological, social, and practical needs, focusing on infor-
mation needs over two consecutive (one-month) assessments. METHODS: The study 
was a longitudinal research. A total of 245 consecutive patients at IDI-IRCCS, Rome, 
were enrolled. They ﬁlled the Edmonton Symptom Assessment System (ESAS) and the 
Need Evaluation Questionnaire (NEQ) at baseline and one month later (n.115). The 
psychometric properties of questionnaires have been well documented in literature. 
ESAS is a questionnaire with 10 items describing cancer related symptoms in the visual 
analogue scales. NEQ is a standardized questionnaire for psychosocial needs. Multiple 
logistic regressions were used to examine the association between information needs 
and patient characteristics. RESULTS: Patients need more information about their 
own disease condition (preference information ranking: prognosis, treatment, exams, 
diagnosis). Patients with higher education (OR 2.20; p  0.052) need to be more 
informed about diagnosis and more involved in their therapeutic choices (OR 2.37; 
p  0.053). Women need physicians to be more sincere with them (OR 2.70; p  0.029). 
Patients, positive to the question on ESAS depression (cut off q7) believe they 
need more explanations about treatments (p  0.005), more comprehensible informa-
tion from health personnel (p  0.015), more sincerity (p  0.039) and more reassur-
ance by clinicians (p  0.007) compared to the negative ones.Still the information 
needs seem to be stable over time: 70 % of patients showed similar ranking at follow-
up. Patients with modiﬁed needs at the one-month assessment (30%) are equally 
divided into two groups. No statically signiﬁcant differences were observed between 
groups. CONCLUSIONS: The results of the study showed that monitoring patients 
understanding and preferences for information, in the complex process of patient-
physician communication, is relevant to tailor exhaustive explanation for each 
patient.
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OBJECTIVES: In a randomized, phase III trial, sunitinib showed superior progression-
free survival over interferon-alfa (IFN-A), 11 vs. 5 mo, respectively (P  0.001), as 
ﬁrst-line mRCC therapy; median overall survival with sunitinib was 2 years (Motzer, 
2009). Here, we report ﬁnal QOL results from this trial. METHODS: 750 treatment-
naïve mRCC patients were randomized 1:1 to receive sunitinib 50 mg orally once-daily 
in 6-week cycles (4 weeks on drug, 2 weeks off), or IFN-A 9 MU subcutaneously 
thrice-weekly. QOL was measured by 9 endpoints: Functional Assessment of Cancer 
Therapy–General (FACT-G), which has 4 subscales; FACT-Kidney Symptom Index–
15 item (FKSI-15), which includes a Disease-Related Symptoms (FKSI-DRS) subscale 
(primary QOL endpoint); and EQ-5D questionnaire’s utility index (EQ-5D Index) and 
visual analog scale (EQ-VAS). Higher scores indicated better outcomes. Patients com-
pleted questionnaires on days 1 and 28 of each cycle. Data were analyzed for the 
intent-to-treat population using mixed-effects models (MM), supplemented with 
pattern-mixture models (PMM). We also compared QOL of patients in the US and 
EU (France, Germany, Italy, Poland, Spain and UK). RESULTS: Patients on sunitinib 
reported better FKSI-15 and FKSI-DRS scores than those on IFN-A, with a signiﬁcant 
difference in overall means across cycles (4.06 and 2.36, respectively; P  0.0001; 
MM). Similarly, differences in means for FACT-G (and all subscales), EQ-5D Index, 
and EQ-VAS all signiﬁcantly favored sunitinib (P  0.05). Per pre-established thresh-
olds, between-treatment differences in mean scores were clinically meaningful for 
FKSI-15, FKSI-DRS, FACT-G, and the FACT-G functional well-being subscale. In the 
US, all endpoints, except the EQ-5D index score, signiﬁcantly favored sunitinib over 
IFN-A (P  0.05). In the EU, 5 of 9 endpoints signiﬁcantly favored sunitinib over 
IFN-A (P  0.05). Across all analyses, PMM and MM results were similar. CONCLU-
SIONS: Sunitinib provides superior QOL over IFN-A, in addition to superior efﬁcacy, 
as ﬁrst-line mRCC therapy, with similar ﬁndings in the US and EU.
